【摘要】 目的该研究的目的主要是估算durvalumab在Ⅲ期非小细胞肺癌(NSCLC)同步放化疗以后巩固治疗中中国地区的成本效果性。方法基于大型Ⅲ期临床试验PACIFIC的数据构建马尔可夫模型。每组的成本生命年(LYs),质量调整生命年(QALYs)及增量成本效果比(ICERs)将会得到估算。使用一元敏感度及概率敏感度分析进行模型稳定性评估。结果 Durvalumab巩固治疗组对比安慰剂组分别产生了2.91QALYs和2.39QALYs,总费用分别是$58 636和$47 349,因此对比安慰剂组,durvalumab的ICER是$22 067/QALY。结论当意愿支付值(WTP)为$30 828时,在中国,不可切除的Ⅲ期非小细胞肺癌同步放化疗以后,durvalumab巩固治疗似乎是一个具有成本效果性的选择。更多还原

【Abstract】 【Objective】 To estimate the cost-effectiveness of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage Ⅲ non-small cell lung cancer(NSCLC) in China. 【Methods】 A mathematical Markov model was established based on data from the clinical phase Ⅲ trial(PACIFIC). The cost, life-years(LYs), quality adjusted life years(QALYs) and incremental cost-effectiveness ratios(ICERs) were estimated in each group. One-way and probabilistic sensitivity analysis were used to test the model stability. 【Results】 Treatment with durvalumab consolidation therapy group versus no consolidation therapy group resulted in 2.91 and 2.39 QALYs, respectively, total costs were $58,636 and $47,349 respectively,and ICER was $22,067 per QALY gained. 【Conclusion】 Durvalumab consolidation therapy after chemoradiotherapy in stage Ⅲ NSCLC was likely to be a cost-effect choice at willingness-to-pay(WTP) threshold of $30,828 per QALY in China.更多还原